Cordlife's Future in Doubt as Civil Claims Total $5.45 Million
Cordlife, a private cord blood bank in Singapore, is facing a significant legal challenge that could impact its operations. The company is being sued by parents who stored their children's cord blood with Cordlife, alleging improper storage and preservation, resulting in damaged or at-risk cord blood units.
The civil claim, filed in the High Court on December 1, seeks damages of at least $5.45 million. The claimants argue that Cordlife's negligence and/or breach of contract led to irreparable damage, with each damaged unit valued at $50,000. The parents also seek reimbursement for expenses and an assessment of damages.
Cordlife's board is assessing the financial impact, acknowledging that a negative outcome would affect its current financial year's performance. The company is seeking advice on the next steps, but it's clear that this legal battle could have far-reaching consequences.
This isn't Cordlife's first regulatory issue. The Ministry of Health (MOH) had previously issued a notice of regulatory action, halting Cordlife's operations due to significant lapses in their midpoint audit. The MOH's decision came after Cordlife voluntarily suspended operations in September, and the company is now reviewing the notice and seeking guidance.
Adding to the turmoil, Cordlife's executive chairman, Mr. Zhai Lingyun, resigned just a month prior to the latest legal developments. The company's board has appointed Mr. Wu Gang as a non-independent non-executive chairman, recognizing the need for steady leadership during these challenging times.
The appointment of Mr. Wu, with his experience in multiple chairmanships and directorships, is seen as a strategic move to navigate the current operational challenges. However, the civil claims and regulatory scrutiny cast a shadow over Cordlife's future, leaving stakeholders and the public awaiting further developments with a sense of uncertainty.
